Evidence map›Paper›PMID 42057329›Full record

Trial reportCancer medicine2026

Fruquintinib Plus TAS-102 With or Without SBRT as Third- Or Later-Line Therapy for Metastatic Colorectal Cancer: Preliminary Results From a Prospective Phase II Trial.

Yi Wang, Jianfen Xu, Linchun Liang, Yunjie Chen, Leizheng Fei, Jing Hu, Jianjiong Li, Yi Lu, Feng Ren, Ke Chen and 10 more

Abstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Yi WangDepartment of Radiotherapy and Chemotherapy, Ningbo No. 2 Hospital, Ningbo, China.ORCID https://orcid.org/0000-0002-6878-4898
Jianfen XuDepartment of Medical Oncology, Ningbo No. 2 Hospital, Ningbo, China.
Linchun LiangOncology Department, Ningbo Mingzhou Hospital, Ningbo, China.
Yunjie ChenHepatopancreatobiliary Surgery Department 2, Ningbo No. 2 Hospital, Ningbo, China.
Leizheng FeiDepartment of Anorectal Surgery, Ningbo Medical Center, Lihuili Hospital, Ningbo, China.
Jing HuDepartment of Oncology Radiotherapy and Chemotherapy, The Affiliated Lihuili Hospital of Ningbo University, Ningbo, China.
Jianjiong LiDepartment of Anorectal Surgery, Ningbo No. 2 Hospital, Ningbo, China.
Yi LuDepartment of Radiation Oncology, Ningbo Medical Center, Lihuili Hospital, Ningbo, China.
Feng RenHepatopancreatobiliary Surgery Department 2, Ningbo No. 2 Hospital, Ningbo, China.
Ke ChenDepartment of Radiochemotherapy, The Affiliated People's Hospital of Ningbo University, Ningbo, China.
Yanping ShenDepartment of Radiochemotherapy, The Affiliated People's Hospital of Ningbo University, Ningbo, China.
Qingsong TaoThe Chemoradiotherapy Center, The First Affiliated Hospital of Ningbo University, Ningbo, China.ORCID https://orcid.org/0000-0001-6390-8938
Zhi FangDepartment of Medical Oncology, Ningbo No. 2 Hospital, Ningbo, China.
Kaitai LiuDepartment of Oncology Radiotherapy and Chemotherapy, The Affiliated Lihuili Hospital of Ningbo University, Ningbo, China.
Hua YeGastrointestinal Hernia Surgery Department, Ningbo No. 2 Hospital, Ningbo, China.
Jing ZhangDepartment of Radiochemotherapy, The Affiliated People's Hospital of Ningbo University, Ningbo, China.
Yunbao XuDepartment of Radiotherapy and Chemotherapy, Ningbo No. 2 Hospital, Ningbo, China.ORCID https://orcid.org/0009-0009-0227-7883
Haoxun MaoDepartment of Anorectal Surgery, Ningbo No. 2 Hospital, Ningbo, China.
Chen ZhangDepartment of Radiotherapy and Chemotherapy, Ningbo No. 2 Hospital, Ningbo, China.ORCID https://orcid.org/0000-0001-9473-1629
Chuangzhou RaoDepartment of Radiotherapy and Chemotherapy, Ningbo No. 2 Hospital, Ningbo, China.

Funding

Medical and Health Science Program of Zhejiang Province 2024KY1564Shanghai YRD Foundation for Innovation in Health Industry 2025-YRDFHI-043
6 · The paper itself

Abstract

Both fruquintinib and TAS-102 monotherapies are guideline-recommended for third-line treatment of metastatic colorectal cancer (mCRC). This study aimed to analyze the preliminary outcomes of fruquintinib combined with TAS-102, with or without stereotactic body radiation therapy (SBRT), as a third- or later-line therapy for mCRC. This prospective, two-arm, phase II study planned to enroll 66 patients with mCRC who were unresponsive to at least two prior lines of therapy. Patients were allocated to either the FTS (fruquintinib + TAS-102 + SBRT) or FT (fruquintinib + TAS-102) group. Eligible patients received fruquintinib (4 mg, qd, days 1-21) and TAS-102 (30 mg/m

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsBenzofuransColorectal NeoplasmsQuinazolinesRadiosurgeryTrifluridineUracilAdultAgedAged, 80 and overDrug CombinationsFemaleHumansMaleMiddle AgedNeoplasm MetastasisBenzofuransDrug CombinationsHMPL-013PyrrolidinesQuinazolinesThymineTrifluridinetrifluridine tipiracil drug combinationUracilfruquintinibmetastatic colorectal cancerSBRTTAS‐102

Identifiers

PMID42057329
PMCPMC13128967

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.